BioCentury | Oct 3, 2016
Clinical News

Timapiprant: Completed Phase III enrollment

...Eleventa and Oxagen announced the completion of enrollment of 212 patients in a double-blind, placebo-controlled, Russian...
...evaluating 50 mg oral timapiprant once daily for 12 weeks. Atopix has exclusive rights from Oxagen...
...is partnered with Eleventa. Atopix Therapeutics Ltd. , Abingdon, U.K. Eleventa Ltd. , Moscow, Russia Oxagen Ltd....
BioCentury | Mar 10, 2014
Clinical News

OC459: Phase IIb data

...of Allergy, Asthma and Immunology meeting in San Diego. Based on the data, Atopix said Oxagen...
...trial with OC459 to treat moderate to severe atopic dermatitis. Atopix has exclusive rights from Oxagen...
...is partnered with Eleventa. Atopix Therapeutics Ltd. , London, U.K. Eleventa Ltd. , Moscow, Russia Oxagen Ltd....
BioCentury | Mar 4, 2014
Clinical News

Atopix reports mixed Phase II asthma data

...further in asthma," but did not disclose specific plans. Atopix has exclusive, worldwide rights from Oxagen Ltd....
BioCentury | Dec 9, 2013
Clinical News

OC459: Phase II started

...is also in Phase II testing to treat asthma. Last year, Atopix acquired rights from Oxagen...
...where Eleventa has rights. Atopix Therapeutics Ltd. , London, U.K. Eleventa Ltd. , Moscow, Russia Oxagen Ltd....
BioCentury | Jun 3, 2013
Company News

Atopix Therapeutics, Medical Research Council, U.K. Technology Strategy Board (TSB) dermatology news

...has completed Phase IIa testing to treat allergic conjunctivitis and allergic rhinitis. In October 2012, Oxagen Ltd....
BioCentury | Apr 15, 2013
Company News

Oxagen board of directors update

Oxagen Ltd., Abingdon, U.K. Business: Drug discovery Appointed: Ian Laing as chairman; co-founder John Bell as deputy chairman; co-founder Nick Cross as a non-executive director; John Gordon, chairman of Quercus Management WIR Staff...
BioCentury | Oct 5, 2012
Financial News

Russian newco Eleventa debuts with Maxwell investment

...Fund said it made an undisclosed investment in Russian newco Eleventa. Eleventa is partnered with Oxagen Ltd....
BioCentury | Dec 14, 2009
Clinical News

OC000459: Completed Phase IIb enrollment

...double-blind, placebo-controlled, European Phase IIb trial evaluating oral OC000459 given once daily for 12 weeks. Oxagen Ltd....
BioCentury | Dec 7, 2009
Financial News

Oxagen completes venture financing

Oxagen Ltd. , Abingdon, U.K. Business: Inflammation, Autoimmune, Endocrine Date completed: 11/20/09 Type: Venture financing Raised: £16 million ($26.5 million) Investors: Novartis Venture Funds; MPM Capital; SV Life Sciences; Advent Venture Partners; Bessemer Venture Partners; Omega...
BioCentury | Nov 24, 2009
Financial News

Oxagen raises L16 million

...Ventures; Bessemer Venture Partners; Omega; Abingworth; IBT; Red Abbey; and The Wellcome Trust also participated. Oxagen's...
Items per page:
1 - 10 of 79
BioCentury | Oct 3, 2016
Clinical News

Timapiprant: Completed Phase III enrollment

...Eleventa and Oxagen announced the completion of enrollment of 212 patients in a double-blind, placebo-controlled, Russian...
...evaluating 50 mg oral timapiprant once daily for 12 weeks. Atopix has exclusive rights from Oxagen...
...is partnered with Eleventa. Atopix Therapeutics Ltd. , Abingdon, U.K. Eleventa Ltd. , Moscow, Russia Oxagen Ltd....
BioCentury | Mar 10, 2014
Clinical News

OC459: Phase IIb data

...of Allergy, Asthma and Immunology meeting in San Diego. Based on the data, Atopix said Oxagen...
...trial with OC459 to treat moderate to severe atopic dermatitis. Atopix has exclusive rights from Oxagen...
...is partnered with Eleventa. Atopix Therapeutics Ltd. , London, U.K. Eleventa Ltd. , Moscow, Russia Oxagen Ltd....
BioCentury | Mar 4, 2014
Clinical News

Atopix reports mixed Phase II asthma data

...further in asthma," but did not disclose specific plans. Atopix has exclusive, worldwide rights from Oxagen Ltd....
BioCentury | Dec 9, 2013
Clinical News

OC459: Phase II started

...is also in Phase II testing to treat asthma. Last year, Atopix acquired rights from Oxagen...
...where Eleventa has rights. Atopix Therapeutics Ltd. , London, U.K. Eleventa Ltd. , Moscow, Russia Oxagen Ltd....
BioCentury | Jun 3, 2013
Company News

Atopix Therapeutics, Medical Research Council, U.K. Technology Strategy Board (TSB) dermatology news

...has completed Phase IIa testing to treat allergic conjunctivitis and allergic rhinitis. In October 2012, Oxagen Ltd....
BioCentury | Apr 15, 2013
Company News

Oxagen board of directors update

Oxagen Ltd., Abingdon, U.K. Business: Drug discovery Appointed: Ian Laing as chairman; co-founder John Bell as deputy chairman; co-founder Nick Cross as a non-executive director; John Gordon, chairman of Quercus Management WIR Staff...
BioCentury | Oct 5, 2012
Financial News

Russian newco Eleventa debuts with Maxwell investment

...Fund said it made an undisclosed investment in Russian newco Eleventa. Eleventa is partnered with Oxagen Ltd....
BioCentury | Dec 14, 2009
Clinical News

OC000459: Completed Phase IIb enrollment

...double-blind, placebo-controlled, European Phase IIb trial evaluating oral OC000459 given once daily for 12 weeks. Oxagen Ltd....
BioCentury | Dec 7, 2009
Financial News

Oxagen completes venture financing

Oxagen Ltd. , Abingdon, U.K. Business: Inflammation, Autoimmune, Endocrine Date completed: 11/20/09 Type: Venture financing Raised: £16 million ($26.5 million) Investors: Novartis Venture Funds; MPM Capital; SV Life Sciences; Advent Venture Partners; Bessemer Venture Partners; Omega...
BioCentury | Nov 24, 2009
Financial News

Oxagen raises L16 million

...Ventures; Bessemer Venture Partners; Omega; Abingworth; IBT; Red Abbey; and The Wellcome Trust also participated. Oxagen's...
Items per page:
1 - 10 of 79